Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Na ïve Patients

Conclusion PCPI is a practical method that predicts overall survival in newly diagnosed myeloma and facilitates broader use of MM cell proliferation for risk stratification. Teaser The plasma cell labeling index (PCLI) prognosticates survival in multiple myeloma (MM) yet is underutilized due to technical difficulty. We retrospectively evaluated multiplex immunohistochemistry (mIHC) in 151 newly diagnosed patients as a clinically feasible alternative to PCLI. The mIHC correlated with PCLI results and was predictive of overall survival for MM.

Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research